(0.35%) 5 118.00 points
(0.29%) 38 351 points
(0.34%) 15 983 points
(-0.69%) $83.27
(2.55%) $1.972
(-0.01%) $2 346.90
(-0.03%) $27.53
(3.04%) $950.15
(-0.11%) $0.934
(-0.16%) $11.01
(-0.34%) $0.798
(1.77%) $93.50
-0.71% $ 66.00
Live Chart Being Loaded With Signals
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies...
Stats | |
---|---|
Volumen de hoy | 552.00 |
Volumen promedio | 12 870.00 |
Capitalización de mercado | 25.05B |
Last Dividend | $0.726 ( 2023-05-01 ) |
Next Dividend | $0 ( N/A ) |
P/E | 70.21 |
ATR14 | $0.166 (0.25%) |
UCB SA Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
UCB SA Finanzas
Annual | 2023 |
Ingresos: | $5.25B |
Beneficio Bruto: | $3.55B (67.50 %) |
EPS: | $1.810 |
FY | 2023 |
Ingresos: | $5.25B |
Beneficio Bruto: | $3.55B (67.50 %) |
EPS: | $1.810 |
FY | 2022 |
Ingresos: | $5.52B |
Beneficio Bruto: | $3.84B (69.64 %) |
EPS: | $2.20 |
FY | 2021 |
Ingresos: | $5.78B |
Beneficio Bruto: | $4.34B (75.11 %) |
EPS: | $5.60 |
Financial Reports:
No articles found.
UCB SA Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.726 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.663 | 2013-05-02 |
Last Dividend | $0.726 | 2023-05-01 |
Next Dividend | $0 | N/A |
Payout Date | 2023-05-18 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $7.46 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.23 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.90 | |
Div. Directional Score | 8.72 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
WBHC | Ex Dividend Junior | 2023-06-29 | Sporadic | 0 | 0.00% | |
LYBC | Ex Dividend Knight | 2023-09-28 | Quarterly | 0 | 0.00% | |
CLLNY | Ex Dividend Junior | 2023-06-16 | Semi-Annually | 0 | 0.00% | |
SLVYY | Ex Dividend Knight | 2023-05-15 | Semi-Annually | 0 | 0.00% | |
HALMY | Ex Dividend Knight | 2023-07-14 | Semi-Annually | 0 | 0.00% | |
AMADY | Ex Dividend Knight | 2023-07-11 | Annually | 0 | 0.00% | |
NDBKY | Ex Dividend Junior | 2023-09-07 | Annually | 0 | 0.00% | |
CRZBY | Ex Dividend Junior | 2023-06-01 | Sporadic | 0 | 0.00% | |
TDHOF | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
HSQVY | Ex Dividend Junior | 2023-10-05 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0656 | 1.500 | 8.69 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0331 | 1.200 | 8.90 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0571 | 1.500 | -0.477 | -0.715 | [0.1 - 1] |
payoutRatioTTM | 0.490 | -1.000 | 5.10 | -5.10 | [0 - 1] |
currentRatioTTM | 1.317 | 0.800 | 8.42 | 6.73 | [1 - 3] |
quickRatioTTM | 0.839 | 0.800 | 9.77 | 7.81 | [0.8 - 2.5] |
cashRatioTTM | 0.329 | 1.500 | 9.28 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.196 | -1.500 | 6.74 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 4.50 | 1.000 | 9.45 | 9.45 | [3 - 30] |
operatingCashFlowPerShareTTM | 5.26 | 2.00 | 8.25 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.96 | 2.00 | 8.52 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.338 | -1.500 | 8.65 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.648 | 1.000 | 2.54 | 2.54 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.120 | 1.000 | 9.59 | 9.59 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.328 | 1.000 | 9.29 | 9.29 | [0.2 - 2] |
assetTurnoverTTM | 0.505 | 0.800 | 9.97 | 7.97 | [0.5 - 2] |
Total Score | 12.54 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 22.86 | 1.000 | 7.79 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0571 | 2.50 | -0.306 | -0.715 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.96 | 2.00 | 9.01 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.34 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 5.26 | 2.00 | 8.25 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.490 | 1.500 | 5.10 | -5.10 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.127 | 1.000 | 9.32 | 0 | [0.1 - 0.5] |
Total Score | 4.90 |
UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico